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Oncogenes Are Here to Stay 
It has been speculated for many years that some cancers 
might represent the consequence of one or several discrete 
genetic changes in the tumor cells . Studies of xeroderma pig-
mentosum (XP) cells revealed genetic lesions that predispose 
cells to be more susceptible to the carcinogenic effects of 
ultraviolet radiation (UV). Although these genes render it more 
likely that XP cells exposed to UV will be converted to the 
transformed state, their genetic defect does not directly convert 
cells toward the tumorigenic phenotype. In contrast to these 
susceptibility genes, cellular oncogenes (c-one) represent a class 
of genes whose protein products can convert normal cells 
directly to the transformed state [1-4]. Recent studies of the 
oncogenes have had a major impact on our understanding of 
carcinogenesis, although the precise role of c-one in individual 
tumors often remains maddeningly obscure. 
Under normal conditions, c-one probably carry out functions 
that are critical to cellular growth and differentiation [5,6] . 
The normal, appropriately regulated versions of these genes 
are often called proto-oncogenes (proto-one). A proto-one can 
be "activated" to function abnormally and contribute to the 
tumorigenic phenotype by either of two mechanisms: by its 
expression at inappropriately high levels, leading to high levels 
of its protein product, or by mutation ofthe sequences encoding 
the protein product of the gene. Using these criteria, activated 
c-one (also called cellular transforming genes) have been found 
in a variety of spontaneous human cancers [1-4], as well as in 
many chemical [7,8] and virus-induced tumors of animals [9], 
including cutaneous tumors [7,10,11]. 
Detection of Oncogenes 
As often happens, technical innovations have led to the 
identification and characterization of these genes. These tech-
nical advances have enabled investigators to obtain clear an-
swers to certain questions that previously would have required 
experiments that were prohibitively complex, might have 
yielded ambiguous results, or could not even have been carried 
out. We owe our current knowledge of cellular transforming 
genes to multiple advances in molecular biology: the discovery 
of restriction endonucleases, the development of molecular 
cloning technology, and the establishment of relatively efficient 
techniques for the stable transfer of genes into mammalian 
cells [12]. 
The initial studies of c-one were carried out by tumor virol-
ogists. It had been recognized for many years that certain 
proteins encoded by the strongly transforming retroviruses 
(such as the src gene product of Rous sarcoma virus) have the 
capacity to directly induce tumorigenic transformation of cul-
tured cells and endow these viruses with their high oncogenic 
potential [13]. It became clear during the late 1970s that each 
viral oncogene (v-onc) had actually been derived from a cellular 
gene that had been stably acquired by the retrovirus. Approxi-
mately 25 different v-one have now been identified. The avail-
ability of these purified v-one genes enabled investigators to 
identify, isolate, and characterize the normal cellular genes 
(proto-one) from which the v-one had been derived. It should 
be emphasized that these studies quickly established that each 
proto-one represented an ordinary cellular gene that had noth-
ing to do with the virus which had enabled the cellular gene to 
be identified. Further investigation also demonstrated that each 
proto-one was conserved in evolution, as is true of many other 
cellular genes. This means that human cells (and cells from 
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other species) contain proto-one that are homologous to the v-
ane of each transforming virus. 
Given this presence in all animal cells of cellular genes that 
are homologous to viral transforming genes, it was logical to 
ask whether cellular DNA obtained from tumors that had not 
been induced by viruses might contain cellular genes that could 
be tumorigenic for tissue culture cells. This phenomenon was 
demonstrated when DNA from human and animal tumor cell 
lines were able to induce tumorigenic transformation of mouse 
NIH 3T3 tissue culture cells [1-4,13]. These results were highly 
significant: in a given tumor, the same gene was consistently 
responsible for inducing cellular transformation, while similar 
preparations of DNA from normal cells were uniformly negative 
in the cell transformation assay. 
Many activated c-one genes have now been isolated by the 
cell transformation assay described above. In this assay, mor-
phologic transformation by these genes represents a genetically 
dominant trait. Some cellular transforming genes that are 
unrelated to known v-one genes have been detected by this 
powerful gene transfer technique [14] . However, most of the c-
one isolated thus far by this procedure have proved to be one 
of the ras genes, which are a family of closely related cellular 
genes that were first identified from the v-one of Harvey and 
Kirsten sarcoma viruses [15]. Point mutations in sequences 
encoding specific amino acids of the transforming ras protein 
products enable them to transform NIH 3T3 and other estab-
lished rodent tissue culture lines. 
Other activated c-one have been identified biochemically by 
molecular hybridization techniques. Burkitt lymphoma was the 
first human tumor shown consistently to express abnormally 
elevated levels of a cellular gene that was a v-onc homolog. In 
this tumor, the cellular gene was c-mye, which is the cellular 
homolog of a viral oncogene (v-mye) that has been found in 
several transforming viruses [16] . c-mye has been activated in 
this class of B-cell tumor by the mechanism of chromosomal 
translocation. It had been previously recognized that virtually 
all Burkitt lymphoma cells possess a chromosomal transloca-
tion which invariably involved a particular region of chromo-
some 8. This region was translocated onto specific regions of 
any one of three other chromosomes: 2, 14, and 22. Following 
the assignment of c-mye to chromosome 8, and the three 
immunoglobulin chain genes (lgK, lgJ.L, and lgi\) to chromosomes 
2, 14, and 22, respectively, it was quickly established that the 
inappropriate expression of c-myc was the consequence of chro-
mosomal translocation involving c-myc and any one of the 
three immunoglobulin genes. The expression of the translo-
cated c-mye gene has been activated by sequences located 
within the immunoglobulin genes, which contain t issue-specific 
enhancers (sequences that specifically interact with the milieu 
of B cells to increase the level of RNA transcription of genes 
in their vicinity). 
Molecular hybridization techniques have also identified sev-
eral c-one that are related to, but distinct from, the authentic 
cellular homologs of v-one genes. For example, amplification 
(increased gene copy number) and elevated expression of a 
cellular gene called N-mye has been found in some human 
neuroblastomas [ 17). This gene was detected by virtue of its 
homology with mye. 
Two other approaches have been utilized to identify cellular 
genes that may turn out to be oncogenes. One method is to 
screen tumors induced by retroviruses that do not carry t heir 
own v-one gene; the purpose of this search is to see whether 
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the viral DNA has integrated preferentially in a particular 
chromosomal site in several different tumors induced by the 
virus. This approach is based on the observation that when 
avian leukosis virus (a retrovirus that does not contain an 
oncogene) induces bursal lymphomas in chickens, it usually 
does so by activating the chicken c-myc gene. In these tumors, 
the viral DNA, which contains an enhancer element, has inte-
grated adjacent to c-myc, leading to c-myc activation [9]. Using 
a similar approach, analysis of other tumors induced by retro-
viruses has identified virally activated cellular genes that are 
not related to any known v-onc but which may also function as 
oncogenes [18]. 
The second strategy has been to analyze the genes involved 
in the breakpoints of chromosomal translocations found to be 
characteristic for certain tumor types (reviewed in [19]) . The 
potential validity of this approach is based on the examples of 
c-myc with Burkitt lymphoma noted earlier and c-abl (the 
cellular homolog of the v-abl oncogene of Abelson leukemia 
virus), which is found at the breakpoint of the Philadelphia 
chromosome t ranslocation associated with most cases of 
chronic myelogenous leukemia. 
Role in Oncogenesis 
Activated c-one have been found in many different histologic 
types of tumors. The activation of c-one usually represents a 
. somatic change that is confined to the tumor cells. In most 
instances, oncogene activation does not appear to be the con-
sequence of a lesion in the proto-one of the germ cells of the 
affected individual. However, there are preliminary data sug-
gesting that some proto-one associated with certain malignan-
cies may not have been entirely normal [20] . 
As noted earlier, the precise role of cellular transforming 
genes in human tumors has not yet been elucidated. In exper-
imental tumors associated with c-one activation, a very high 
proportion of the tumors contain the same activated gene [7-
9]. By contrast, activated oncogenes have usually been detected 
in only a minority of spontaneously arising tumors of a given 
histologic type. This observation suggests that activation of a 
particular oncogene is not absolutely necessary to develop what 
seems to be a particular type of tumor. Even in those tumors 
in which activated oncogenes have beeen found, it is not yet 
clear whether these changes play a major role in the early 
events of the cancer process. A wealth of data suggests, however, 
that oncogene activation can enchance the malignant potential 
of a given cell. 
The data from experimental tumorigenesis and clinical ob-
servation strongly suggests that the progression from a normal 
to a malignant cell does not occur as a single-step process 
(reviewed in [1]) . Human cells appear to be particularly difficult 
to transform in vitro to the fully tumorigenic phenotype. Re-
sults obtained with activated c-one in primary rodent cells have 
been consistent with the multistep hypothesis of tumorigenesis. 
Although an activated e-ras gene can induce full transformation 
of established tissue culture cell lines, this same gene may not 
by itself induce full transformation of primary rodent cells. 
However, the primary rodent cells can be transformed to the 
tumorigenic phenotype by introducing a second oncogene such 
as myc in addition to the activated e-ras [1]. 
Many tumors have been described that contain more than 
one activated oncogene (reviewed in [1]) . It seems reasonable 
to conclude that the oncogenic activity of two oncogenes will 
be greater than that of either one by itself. It also appears likely 
that particular combinations of oncogenes may have greater 
malignant potential than others. Some investigators believe 
that certain oncogenes (such as myc) function principally as 
immortalization genes (that prolong the lifespan of the cell), 
while other oncogenes (such as ras) function principally as 
genes that transform cells morphologically. 
Some oncogenes may be tissue specific in their tumorigenic 
activity. Instructive results have been obtained with c-fos, 
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((5]; the cellular homolog of v-fos, found in two osteosarcoma 
viruses). This gene is expressed at high levels in placenta during 
normal embryogenesis, but its expression in chondrocytes at 
levels similar to those in placenta leads to the induction of 
osteogenic sarcomas in mice. These results emphasize the no-
tion that inappropriate expression, rather than merely the level 
of expression, may have a determining influence on tumori-
genicity. One laboratory has found consistent activation of 
other genes correlates closely with a given type of tumor (14]. 
On the other hand, activated ras and myc genes have been 
detected in many different tumor types, suggesting that these 
genes may contribute to the tumorigenic phenotype in widely 
divergent tumors. 
Function of Oncogene Encoded Proteins 
It is very likely that c-one serve important functions in 
normal growth and development, given their high degree of 
conservation among widely divergent species and their capacity 
to alter the proliferative capacity of cells. In addition to being 
present in all vertebrates, many c-one have also been found in 
invertebrate animal species, such as Drosophila. Even more 
striking has been the identification of ras genes in yeast (21]. 
Since these genes act on cells through their protein products, 
one genes should probably be grouped according to the functions 
of these proteins. An extremely important area for future 
research will be to elucidate the mechanisms by which these 
proteins act and to determine the cellular pathways in which 
they fall. Results obtained thus far suggest that there are several 
classes of these proteins [22]. 
The ras genes of Harvey and Kirsten sarcoma viruses were 
the first example of two different one genes recognized as being 
related to each other. The ras gene family is comprised of at 
least three different biologically active genes in mammals 
[ 15]. The three genes encode proteins that are closely related 
to each other, are found at the plasma membrane, possess 
GTPase activity that is significantly lower in activated ras 
genes, and share homology with so-called G proteins (regulatory 
proteins of the adenylate cyclase system). Microinjection of 
ras-specific antibody into NIH 3T3 cells prevents their 
undergoing DNA synthesis, suggesting that ras protein is es-
sential for the growth of these cells and perhaps other cell types 
[6]. 
Experiments in yeast suggest that the yeast ras also subserve 
a function that is essential to their life cycle. In addition, 
mammalian ras genes can substitute functionally for yeast ras, 
and activated versions of yeast ras genes can morphologically 
transform mouse NIH 3T3 cells [21]. These results suggest 
that these genes probably function similarly in mammalian 
cells and in yeast. Since it is in principle much easier to develop 
cell mutants in yeast than in higher eukaryotic cells, it seems 
likely that elucidation of the cellular pathway for ras protein 
function in yeast will have direct implications for the function 
of the mammalian ras proteins. 
Other one genes have been found to be part of another large 
gene family, which has been designated the src gene family [22] 
because the v-src gene of Rous sarcoma virus is the prototype 
for the proteins they encode. Most of their proteins possess a 
tyrosine kinase activity that correlates closely with their trans-
forming activity. 
Some proto-one related to v-onc have turned out to be genes 
that nonvirologists have studied as cell-encoded proteins. The 
v-erb8 gene, which is a member of the src gene family, repre-
sents a truncated version of the epidermal growth factor (EGF) 
receptor [23]. This gene has been found in the avian erythro-
blastosis virus; as its name implies, this virus induces erythro-
blastosis in chickens. Elevated expression of this gene has been 
reported in a variety of epithelial tumors, including some cu-
taneous squamous cell carcinomas [11]. The sis gene found in 
another retrovirus represents a somewhat altered version of the 
gene that encodes platelet-derived growth factor (PDGF), 
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which is believed to play a significant role in wound healing 
[24]. 
The proteins encoded by myc, fos, and several other onco-
genes are found in t he nucleus, where some appear to be DNA 
binding proteins. Marked changes in t he expression of fos have 
been noted shortly after stimulation of quiescent tissue culture 
cells (5]. 
Future Prospects 
It seems probable that some of t he most interesting chapters 
in research on these genes are yet to be written. The analysis 
of o ncogenes has focused principally on their role in malignant 
tumors. The cont inued study of these genes and their protein 
products in malignancies will a lmost certainly contribute sig-
nificant new knowledge to the field of oncogenesis. Further 
exploration of c-one may also lead to new insights in cell 
biology, molecular evolution, and the pathogenesis of nonma-
lignant disease, such as those conditions associated with ab-
normalities of cell proliferation or differentiation. For example, 
psoriasis or Darier's disease represents a disorder whose path-
ogenesis might involve inappropriate (but reversible) proto-one 
expression. 
Douglas R. Lowy, M.D., Chief 
Laboratory of Cellular Oncology 
National Cancer Institute 
Bethesda, Maryland 
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